Monoclonal antibodies against the SARS-CoV-2 spike protein, notably, those developed by
Regeneron Pharmaceuticals and Eli Lilly and Company have proven to provide protection …

Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option
against COVID-19. Because rapidly emerging virus mutants are becoming the next major …

SARS-CoV-2 can mutate to evade immunity, with consequences for the efficacy of emerging
vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant …

Emerging variants of concern for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) can transmit more efficiently and partially evade protective immune …

Abstract SARS-CoV-2 and SARS-CoV share a common human receptor ACE2. Protein-
protein interaction structure modeling indicates that spike-RBD of the two viruses also has …

The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …

Abstract The SARS-CoV-2 B. 1.1. 529 variant (Omicron) contains 15 mutations on the
receptor-binding domain (RBD). How Omicron would evade RBD neutralizing antibodies …

As the coronavirus disease 2019 (COVID-19) pandemic continues, there is a strong need for
highly potent monoclonal antibodies (mAbs) that are resistant against severe acute …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …

In recent months, additional Omicron variants of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), including the BA. 5 sublineage BF. 7 and BQ. 1.1 and the BA …